Global Health Ltd. engages in the provision of healthcare, pathology, and other medical services. The company is headquartered in New Delhi, Delhi. The company went IPO on 2022-11-16. Medanta delivers advanced, end-to-end healthcare in Delhi, Gurugram, Indore, Ranchi, Patna and Lucknow through its network of five hospitals, six Mediclinic, diagnostic laboratories, homecare and telemedicine services. The company provides treatments for coronary artery disease, head and neck cancer, acute myeloid leukemia, epilepsy, hip fracture, Parkinson's disease, refractive error, prostate cancer, chronic kidney disease, cerebral stroke, sepsis, liver cirrhosis, rheumatoid, arthritis, hypertension, diabetes, bronchial asthma, stomach cancer, and chronic otitis media. Medanta specializes in cardiac surgery, nephrology, urology, andrology, dermatology, ophthalmology, radiology and imaging, dental sciences, and interventional cardiology, among others. Its facilities and services include medicine delivery, air ambulance, patient support services, and others.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.